The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression

The transcription factor ZNF217 is a candidate oncogene in the amplicon on chromosome 20q13 that occurs in 20% to 30% of primary human breast cancers and that correlates with poor prognosis. We show that Znf217 overexpression drives aberrant differentiation and signaling events, promotes increased s...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Littlepage, Laurie E., Adler, Adam S., Kouros-Mehr, Hosein, Huang, Guiqing, Chou, Jonathan, Krig, Sheryl R., Griffith, Obi L., Korkola, James E., Qu, Kun, Lawson, Devon A., Xue, Qing, Sternlicht, Mark D., Dijkgraaf, Gerrit J. P., Yaswen, Paul, Rugo, Hope S., Sweeney, Colleen A., Collins, Colin C., Gray, Joe W., Chang, Howard Y., Werb, Zena
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2012
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3546490/
https://ncbi.nlm.nih.gov/pubmed/22728437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0093
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia